UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular mechanisms in multiple myeloma drug resistance

Journal of Clinical Pathology, 2016-02, Vol.69 (2), p.97-101

2016

Volltextzugriff (PDF)

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica (Roma), 2012-01, Vol.97 (1), p.64-72

2012

Volltextzugriff (PDF)

Resistance to Targeted Therapies in Multiple Myeloma

1st Edition 2021, 2021

Volltextzugriff (PDF)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma

Cells (Basel, Switzerland), 2021-12, Vol.10 (12), p.3464

2021

Volltextzugriff (PDF)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma

Leukemia research reports, 2023-01, Vol.20, p.100393-100393, Article 100393

2023

Volltextzugriff (PDF)

Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance

Clinical & translational immunology, 2018, Vol.7 (1), p.e1007-n/a

2018

Volltextzugriff (PDF)

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA

Blood cancer journal (New York), 2023-07, Vol.13 (1), p.113-113, Article 113

2023

Volltextzugriff (PDF)

The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma

Annals of nuclear medicine, 2014-10, Vol.28 (8), p.805-811

2014

Volltextzugriff (PDF)

Multiple Myeloma in the Culturally and Linguistically Diverse Southwestern Sydney, Australia

Blood, 2023-11, Vol.142 (Supplement 1), p.6642-6642

2023

Volltextzugriff (PDF)

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Blood, 2020-11, Vol.136 (Supplement 1), p.42-43

2020

Volltextzugriff (PDF)

Prognostic impact of calculation methods for FLT3-ITD allelic ratio and NPM1 status in AML patients

Pathology, 2019-02, Vol.51, p.S125-S125

2019

Volltextzugriff (PDF)

Comparing the area under the curve and peak height methods in the calculation of FLT3‐ITD allelic ratio

International journal of laboratory hematology, 2020-10, Vol.42 (5), p.e234-e236

2020

Volltextzugriff (PDF)

Circulating tumour DNA in multiple myeloma – analysis of the KRAS/NRAS/BRAF mutation in a local cohort

Pathology, 2019-02, Vol.51, p.S127-S127

2019

Volltextzugriff (PDF)

Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

Bone marrow transplantation (Basingstoke), 2021-03, Vol.56 (3), p.738-740

2021

Volltextzugriff (PDF)

P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S196-S196

2023

Volltextzugriff (PDF)

A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

European journal of haematology, 2024-10, Vol.113 (4), p.521-529

2024

Volltextzugriff (PDF)

3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA

Experimental hematology, 2024-08, Vol.137, p.104498, Article 104498

2024

Volltextzugriff (PDF)

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.6927-6929

2022

Volltextzugriff (PDF)

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia

Internal medicine journal, 2023-05, Vol.53 (5), p.819-824

2023

Volltextzugriff (PDF)

Validation of cebpa mutation testing for use in a clinical setting

Pathology, 2017-02, Vol.49, p.S109-S109

2017

Volltextzugriff (PDF)

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Internal medicine journal, 2023-04, Vol.53 (4), p.599-609

2023

Volltextzugriff (PDF)

Wilms tumour gene 1 (WT1) mutations in acute myeloid leukemia (AML)

Pathology, 2016-02, Vol.48, p.S100-S100

2016

Volltextzugriff (PDF)

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia

Internal medicine journal, 2021-10, Vol.51 (10), p.1707-1712

2021

Volltextzugriff (PDF)

A quality assurance project for the molecular diagnosis of myeloproliferative neoplasms

Pathology, 2017-02, Vol.49, p.S62-S62

2017

Volltextzugriff (PDF)

1 – 25 von 265

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(228)
Mit Volltextzugriff
(244)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(90)
Humans
(66)
Female
(42)
Animals
(39)
Male
(31)
Physical Sciences
(26)
Technology
(26)
Science & Technology - Other Topics
(25)
Multidisciplinary Sciences
(22)
Mice
(21)
Adult
(18)
Physics
(18)
Middle Aged
(17)
Multiple Myeloma
(17)
Aged
(16)
Materials Science
(14)
Medicin Och Hälsovetenskap
(13)
Oncology
(13)
Engineering
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Molecular mechanisms in multiple myeloma drug resistance

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Resistance to Targeted Therapies in Multiple Myeloma

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma

Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA

The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma

Multiple Myeloma in the Culturally and Linguistically Diverse Southwestern Sydney, Australia

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Prognostic impact of calculation methods for FLT3-ITD allelic ratio and NPM1 status in AML patients

Comparing the area under the curve and peak height methods in the calculation of FLT3‐ITD allelic ratio

Circulating tumour DNA in multiple myeloma – analysis of the KRAS/NRAS/BRAF mutation in a local cohort

Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy

A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia

Validation of cebpa mutation testing for use in a clinical setting

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Wilms tumour gene 1 (WT1) mutations in acute myeloid leukemia (AML)

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia

A quality assurance project for the molecular diagnosis of myeloproliferative neoplasms

Suchergebnisse filtern